and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.

A newly discovered natural peptide called BRP shows promising weight loss effects without the side effects of Ozempic. Learn how this non-incretin hormone could revolutionize obesity treatment.

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Novo Nordisk has been on the hunt for differentiated obesity drugs that could complement its blockbuster GLP-1 agonist ... it can lead to greater weight loss as part of a drug combination and ...

The class of drugs – GLP-1 receptor agonists – has been around for two decades as a diabetes medication. Their popularity as a tool for weight loss skyrocketed after the US Food and Drug ...

ChipMonk Baking has been in the game of making healthier cookies since long before GLP-1 agonist weight-loss drugs like Ozempic ... company says aims to boost natural levels of GLP-1.

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth up to $2bn as the Wegovy (semalgutide) developer ...

and GLP-1 agonists such as semaglutide (in people with both HFpEF and obesity). These drugs help people lose weight and have also been shown to reduce hospitalization for heart failure.